|Head and Neck|
|Impassion 130: PD1 Immunotherapy for breast cancer|
|PALOMA 3: Palbociclib in HR HER2- breast cancer|
|Chidamide in 2nd line breast cancer|
|Erlotinib superior to gemcitabine for EGFR NSCLC|
|JAVELIN: Avelumab and axitinib for kidney cancer|
|GETUG 12 trial for localised high risk prostate cancer|
|SOLO1: Olaparib maintenance for ovarian cancer|
|Checkmate 142: Combination immunotherapy for mCRC|
For more on the breast cancer news from the conference, Dr Matteo Lambertini offered his highlights.
For key data from melanoma trials, Dr Teresa Amaral summarised key sessions from the conference.